Quoin Pharmaceuticals signs at-the-market share sales agreement with Leerink Partners
QNRX•Quoin Pharmaceuticals entered an at-the-market sales agreement with Leerink Partners on November 4, 2026, to sell American Depositary Shares. Leerink Partners will receive 3% of gross proceeds, and each ADS represents 35 ordinary shares.
1. Share sales agreement
Quoin Pharmaceuticals entered an at-the-market sales agreement with Leerink Partners on November 4, 2026, to sell American Depositary Shares through the agent. Leerink Partners will receive 3% of gross proceeds from sales, and each ADS represents 35 ordinary shares.
